Pfizer’s $345 Million EpiPen Settlement Receives Court Approval

The EpiPen buyers leading price-gouging litigation against two top drugmakers secured final approval Wednesday from a federal judge in Kansas for their $345 million settlement with Pfizer Inc. affiliates that formerly manufactured the lifesaving allergy treatment sold by Mylan NV.

Judge Daniel D. Crabtree signed off on the agreement, which resolves class action antitrust claims brought against Pfizer in the U.S. District Court for the District of Kansas on behalf of “end payers” like insurers, pension funds, and consumers. The deal includes a $115 million payday for their attorneys.

The settlement doesn’t directly affect the claims against Mylan or ...